Invitrall
Founded 2024 · 4 employees on LinkedIn · 1 known investors
Invitrall develops long-lasting, disease-representative human skin organoids from reprogrammed human cells, combining cell reprogramming, organoids, and machine learning to create human preclinical models. Its platform supports efficacy and repeated-dose toxicity testing for pharmaceutical and dermocosmetics companies developing skin drugs and cosmetics, as an alternative to animal testing.
Founders & leadership
GL
Gabriel Lohn CostaCEO
VC
Viviana Costa GagosiaCSO
Investors · 1
Frequently asked questions
- What does Invitrall do?
- Invitrall develops long-lasting, disease-representative human skin organoids from reprogrammed human cells, combining cell reprogramming, organoids, and machine learning to create human preclinical models. Its platform supports efficacy and repeated-dose toxicity testing for pharmaceutical and dermocosmetics companies developing skin drugs and cosmetics, as an alternative to animal testing.
- Who are Invitrall's investors?
- Invitrall's investors include GRIDX.